Auto saved by Logseq

pages/STOP2030___Web___Posts.md

@@ -3,7 +3,8 @@
 - # REALISE study registration
 	- ## The design of our REALISE study is now complete, and published
 	- #+BEGIN_VERSE
-	  At STOP2030 we want to provide a pharmacological tool that helps at delivering WHO's elimination goals for soil-transmitted helminthiasis (STH). That is why we're happy to announce that we've completed the design of the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness). The details of the trial have been published in clinicaltrials.gov and the Pan African Clinical Trial Registry, and are now ready to be delivered to the Institutional Review Boards (IRBs) in Ghana and Kenya, the two countries were it will be carried out.
+	  At STOP2030 we want to provide a pharmacological tool that helps at delivering WHO's elimination goals for soil-transmitted helminthiasis (STH). We're happy to announce that we've completed the design of the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness). 
+	  The details of the trial have been published in clinicaltrials.gov and the Pan African Clinical Trial Registry, and are now ready to be delivered to the Institutional Review Boards (IRBs) in Ghana and Kenya, the two countries were it will be carried out.
 	  
 	  The design of the clinical trial was lead by the teams at ISGlobal and Liconsa, with help from other members of our Consortium. The study itself is a Cohort Event Study aimed at evaluating the safety and effectiveness of our fixed-dose coformulation (FDC) of albendazol and ivermectin within large populations, matched against the standard dose albendazole currently in use against STH. We expect to recruit around 20 thousand school-aged children between 5 and 17 years old between the two countries.